Nuvation BioNUVB
Recorded

Nuvation Bio Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Farzin HaqueBiotech Analyst

Hi, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It is my pleasure to introduce David Hung, CEO, and Philip Sauvage, CFO of Nuvation Bio. Maybe, David, you can start off giving a quick one-minute intro to the company.

David HungCEO

Yeah. We have, I guess, focus on three programs. IBTROZI is a commercial-stage asset approved a year ago in the U.S., also approved in China and Japan, and about to be approved in Europe. We have had about a year of sales, and we are already a market leader in our space. We are also a market leader in first-line patients. If you look at our quarter-on-quarter growth in the last quarter, it was up 18% in spite of a 20% drop in new patient alerts in testing for ROS1. I would say we are about $100 million for the year so far, and I think that if you look at our data, our 90% response rate and 50-month duration of response have not been matched by anyone in the first-line space.

David HungCEO

In the second-line indication, our 56% response rate and 66% intracranial response rate have not been matched by anyone in the second-line indication. If you look at our tolerability and safety, we are now the only brain-penetrant ROS1 TKI that does not have a CNS warnings and precautions. I would say that that program is going very well. Our second program, safusidenib, is a mutant IDH1 glioma drug. We are in four studies right now. Unlike the only competitor in the space, vorasidenib, which is approved only in the low-grade glioma indication, we have shown activity in both low-grade and high-grade glioma. If you look at vorasidenib's most recent three-year data, in the low-grade indication, their response rate was 21%. In the same indication, our response rate was 52%. If you look at their progression-free survival at three years, in the low-grade indication, it was 52% PFS.

David HungCEO

Ours was 79%. We think that this drug is extremely active in the low-grade indication. If you look at vorasidenib's response in high-grade glioma, it was zero. Ours was 17%, with a third of those being complete responses. Again, we believe that safusidenib is extremely active in low-grade setting as well as the high-grade setting. We are in a number of trials. Our earliest data will read out in 2027. We are going to see grade 3 oligo patients, a form of high-grade glioma, that we will start to have data in the second half of next year. We are also enrolling patients in a post-vorasidenib failure indication. That is clearly a really big indication, and we will also have some data in that indication probably in the second half of next year. Then we have two other trials reading out with a PFS endpoint later on in 2029.

David HungCEO

But our first data on response rate will start to read out in the second half of next year. We believe that if you look at the precedent set by companies like Chimerix, where their drug was approved on 11 responses in 50 patients, we think 20% or so response rate or higher is potentially sufficient to get approval in an indication where there is no other therapy. And given the activity that we've seen with safusidenib in both the low-grade and high-grade indications, we think that we're very bullish on that program. Our third program is a drug-drug conjugate program. DDCs are like an ADC without the A, so no antibody. We're fusing two small molecules together. Because small molecules are so much smaller than antibodies, they can go places that antibodies can't go, and they can also do things that antibodies and antibody drug conjugates can't do.

David HungCEO

I think a very exciting example of a DDC, actually the only company that we are aware of that has a program like ours, is Halda. As you know, Halda's prostate drug, based on 10 patients of data, was acquired for $3 billion, and they just recently announced post-existing response rates of 69%. Their molecule is basically a DDC. We have an entire platform based around this DDC concept, and we're going to be making an announcement on that program in the next six weeks or so. A very brief announcement, and then we're going to follow that up with an R&D day earlier next year. So, we think that's an extremely exciting platform technology that could yield many molecules to the pipeline.

Farzin HaqueBiotech Analyst

Makes sense. I want to start with the safusidenib, because I think that's the clear value driver in the future. So if it works across the newly diagnosed, recurrent, high-grade, post-VORA, how should we think about the addressable patient population? Which one is the biggest driver for the commercial opportunity?

David HungCEO

So, if you look at the division of low-grade and high-grade glioma among brain tumors, it's about 50/50. But the difference is, IDH1 mutations make patients actually live longer. So if you look at the progression-free survival of IDH1 mutant brain tumors, it's actually extremely long compared to non-IDH1 driven. But IDH1 is also relentless, so they will always continue to grow. So low-grade patients can live 20-plus years. Even high-grade IDH1 mutant gliomas like astrocytoma, even GBM, they can still live six-plus years, unlike regular GBM. So, what's unique about IDH1 as a mutation is that it makes the tumor relentless, but it also makes the patient survive for long periods of time.

David HungCEO

You do need to treat these tumors because, especially when they occur in younger patients, and they will grow relentlessly, they will compromise things like your neuro status, your vision, your hearing, all the things that you expect brain tumors to do. It is very important that you address it. You cannot give repeated surgeries to young patients. You cannot just keep cutting out parts of the brain. You cannot continually give radiotherapy, which is clearly very damaging to brain tissue. You cannot give chemotherapy. No patient wants to take chemotherapy forever. You do need an oral therapy. We think our once-a-day pill is a very attractive option, and we can show that we continue to have the results that we have shown so far.

David HungCEO

The reason the market opportunity is so large is because when you have 20 years of patients taking the drug, you are talking about a revenue stacking opportunity you just do not see in general in oncology. That is in the low-grade setting. In the high-grade setting, even though it is shorter than low-grade, we are still talking about up to 6+ years in the high-grade setting, so that is still an attractive option. Even though the roughly 50/50 split of high-grade to low-grade is how the indications break out, the longer duration of therapy likely in low-grade indications makes that a more compelling commercial opportunity. When I mentioned earlier that vorasidenib has a 21% response rate in low-grade, we have a 52% response rate in low-grade.

David HungCEO

When people ask us, "Why do we believe this drug will work after vorasidenib?" Well, we have 31 percentage points more response rate in the same indication. We do believe SAFU will work after vorasidenib. We believe that if it works after vorasidenib, people will use it after vorasidenib, and even instead of vorasidenib. We actually believe that is the path to get the entirety of the lower market.

Farzin HaqueBiotech Analyst

Maybe to rephrase that, like, mechanistically, how SAFU works differently from VORA to give that differential responses?

David HungCEO

We've made the point before that, even though they both hit IDH1, we are seeing activities with safusidenib that you don't see with vorasidenib. vorasidenib's main adverse event is liver function test abnormalities. We don't generally see that. If you look at our adverse events, even though almost all of them are grade 1, we do see, out of our top seven adverse events, five of them are immune-related. We see things like alopecia, rash, arthralgia, like rheumatoid arthritis, pruritus. We believe that if you look at our responses, they take 6-12 months to kick in, sometimes even longer. In fact, even between years two and year three, we had an additional 8% response rate, going from 44% to 52% in our recent publication.

David HungCEO

When you see those really long times to responses, and then really durable responses, we have a GBM that's been in the CR for three and a half years. We have another high-grade oligodendroglioma that's been gone for two years. When you see those really long onset to response, and then very durable responses, it's very reminiscent of immuno-oncology agents. We actually believe that safusidenib has a significant immune component to its activity, and we believe that that differentiates it from VORA and why we believe we will see responses after VORA failure. Also, we're already seeing responses in indications that VORA's response rate is zero.

Farzin HaqueBiotech Analyst

Got it. Any color on the enrollment across SIGMA, the oligodendroglioma study, and the post-VORA study?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day